Curated News:

Medical Meetings

Add to Favorites Subscribe Share
fbshare-Medical Meetings

Showing results

4150 of 3811
uclahealthlogo.gif
  • Embargo expired:
    29-Sep-2019 10:30 AM EDT

Article ID: 719796

Adding Targeted Therapy Drug to Hormone Therapy Helps Women with Aggressive Breast Cancer Live Longer

University of California, Los Angeles (UCLA), Health Sciences

A study led by UCLA researchers found that adding ribociclib, a targeted therapy drug, to standard hormone therapy has been shown to significantly improve overall survival in postmenopausal women with advanced hormone-receptor positive/HER2- breast cancer, one of the most common forms of the disease.

Released:
29-Sep-2019 4:05 AM EDT
Newswise: Wrist-Worn Step Trackers are as Accurate in Predicting Patient Health as Standardized Clinical Walking Tests, Researchers Find
  • Embargo expired:
    29-Sep-2019 6:50 AM EDT

Article ID: 719580

Wrist-Worn Step Trackers are as Accurate in Predicting Patient Health as Standardized Clinical Walking Tests, Researchers Find

Intermountain Healthcare

In a new study, researchers at Intermountain Healthcare in Salt Lake City found that steps measured through a step tracker worn on the wrist can be used to estimate exercise capacity and determine the health status of patients, rather than the standardized six-minute walk distance test, which is usually conducted in a clinical setting.

Released:
25-Sep-2019 9:15 AM EDT
Newswise: New blood test capable of detecting multiple types of cancer
  • Embargo expired:
    28-Sep-2019 2:30 AM EDT

Article ID: 719645

New blood test capable of detecting multiple types of cancer

Dana-Farber Cancer Institute

A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.

Released:
25-Sep-2019 10:05 PM EDT
Newswise: Researchers show genetic mutations in advanced lung cancer may predict improved outcomes

Article ID: 719728

Researchers show genetic mutations in advanced lung cancer may predict improved outcomes

Yale Cancer Center

According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in patients using pembrolizumab (Keytruda) to treat non-small cell lung cancer (NSCLC).

Released:
27-Sep-2019 12:00 PM EDT
crf-corporate-logo_1.png

Article ID: 719727

Shortened Three-month DAPT Duration After PCI Demonstrates Low Rate of Adverse Events in High-Bleeding Risk Patients

Cardiovascular Research Foundation (CRF)

Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not increase myocardial infarction (MI) or stent thrombosis (ST) in high bleeding risk (HBR) patients treated with a contemporary drug-eluting stent.

Released:
26-Sep-2019 9:05 PM EDT
crf-corporate-logo_1.png

Article ID: 719724

Ticagrelor Without Aspirin Three Months After Successful PCI and DAPT Reduces Major Bleeding Without Increasing the Risk of Adverse Events

Cardiovascular Research Foundation (CRF)

New data from the randomized, placebo-controlled TWILIGHT trial found that compared to ticagrelor plus aspirin, ticagrelor monotherapy reduces bleeding events without increasing the risk of death, myocardial infarction, or stroke in high-risk patients who have undergone successful percutaneous coronary intervention (PCI) and completed three months of dual antiplatelet therapy (DAPT).

Released:
26-Sep-2019 8:05 PM EDT
crf-corporate-logo_1.png

Article ID: 719726

Biodegradable Polymer Everolimus-eluting Stent with Shortened DAPT is Safe and Effective for PCI in Patients with Unprotected Left Main Coronary Artery Disease

Cardiovascular Research Foundation (CRF)

New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe and effective compared to a conventional durable polymer everolimus-eluting stent (DP-EES) followed by 12 months of DAPT in patients undergoing PCI for unprotected left main coronary artery (uLMCA) disease.

Released:
26-Sep-2019 8:05 PM EDT
ato-logo.gif

Article ID: 719666

Noninvasive radiation treatment offers long-term benefits to patients with high-risk heart arrhythmias

American Society for Radiation Oncology (ASTRO)

Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically reduce episodes of rapid, abnormal heartbeats for more than two years, offering hope to patients who have exhausted other treatment options. Findings were presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Released:
26-Sep-2019 11:05 AM EDT
ato-logo.gif

Article ID: 719675

PACIFIC survival rates explained: Lung cancer spread reduced, new distant growth most often in the brain

American Society for Radiation Oncology (ASTRO)

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The update, which provides greater insight into the landmark study that changed the standard of care for patients with stage 3 unresectable non-small-cell lung cancer (NSCLC), were presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Released:
26-Sep-2019 11:05 AM EDT

Showing results

4150 of 3811

Chat now!